Elena Verzoni

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

Brian I. Rini, Sumanta K. Pal, Bernard Escudier et al. · The Lancet Oncology · 2019 · 248 citations

Urology, Genitourinary Cancer, Tivozanib Versus Sorafenib +8

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

Emilio Bajetta, Laura Catena, Giuseppe Procopio et al. · Cancer Chemotherapy and Pharmacology · 2006 · 241 citations

Oncology, Medicine, Are Capecitabine +7

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Katriina Peltola et al. · New England Journal of Medicine · 2024 · 111 citations

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

Sergio Bracarda, Roberto Iacovelli, Luca Boni et al. · Annals of Oncology · 2015 · 105 citations · Full text

Urology, Oncology, Genitourinary Cancer +5

Sequential use of sorafenib and sunitinib in advanced renal‐cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases

Camillo Porta, Giuseppe Procopio, Giacomo Cartenì et al. · British Journal of Urology · 2011 · 87 citations